March 27, 2015

DrugDev Founder Melissa Easy is 2015 PBJ 40 Under 40 Honoree

DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree

Created new technology paradigm used by 9 of top 10 pharmaceutical sponsors to conduct more clinical trials

DrugDev announced company founder and current President of DrugDev SiteStart Melissa (Liss) Easy was named to the 2015 Philadelphia Business Journal 40 Under 40.

The 40 Under 40 list spotlights 40 dynamic, up-and-coming leaders less than 40 years of age for their professional accomplishments and community involvement. Winners are honored at an awards program in May, and profiled in a special supplement of the Philadelphia Business Journal.

Lyn Kremer, Publisher of the Philadelphia Business Journal, said, “Liss Easy exemplifies the kind of forward-thinking entrepreneur who transforms their industry. We hope Liss and her colleagues on this year’s honoree list will inspire others to innovate and drive continued growth in our local, national and global economy.”

Liss founded DrugDev because she saw major inefficiencies in the process of matching clinical trial investigators to pharma protocols. Her mission is to bring sponsors and investigators closer together by focusing on the needs of the doctors and providing them with better technology-driven solutions, service, and more open communication.

DrugDev started with a network of cardiologists, and has since grown through referral and invitation into the world’s largest opted-in investigator network and data sharing platform, today reaching more than 80,000 active investigators in 115 countries who are actively seeking new clinical trial opportunities. DrugDev enables sponsors, CROs and sites to leverage modern technologies to do more trials together.

DrugDev President and CEO Ibraheem Mahmood said, “Liss is guided by a steadfast belief that technology can build and strengthen relationships within the pharmaceutical industry and improve clinical research with the goal of bringing many more new drugs to patients. She is an extraordinary example of achievement in this new phase of our industry and is an amazing role model for her peers, and I congratulate her on this tremendous honor.”

Liss Easy said, “I’m very grateful and honored to be among these remarkable honorees, and feel much of the credit for this recognition should go to my colleagues at DrugDev who come to work every day with a passion to improve people’s lives by improving the clinical trial process.”